LAUSR

Loss of myelination is common among neurological diseases. It causes significant disability even death if it not treated instantly. Different mechanisms involve in the pathophysiology of demyelinating diseases, such as genetic background, infectious, and autoimmune inflammation. Recently, regenerative medicine and stem cell therapy showed hopeful ways in treatment of demyelinating disorders Stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells (ASCs) can differentiate into oligodendrocyte progenitor cells (OPCs) which may convert to oligodendrocytes (OLs) and recover myelination. IPSCs provide an endless source for OPCs generation. However, the restricted capacity of proliferation, differentiation, migration, and myelination of iPSC-derived OPCs is a notable gap for future studies. In this article, we first reviewed the stem cell therapy in demyelinating diseases. Secondly, methods of different protocols were discussed among in vitro and in vivo studies on iPSC-derived OPCs to contrast OPCs' transplantation efficacy. Lastly, we reviewed results of iPSCs-derived OLs production in each demyelination models.